www.affiris.com
Friday, June 15, 2012
A WORLD'S FIRST: A Parkinson's Vaccine
Phase I study of the AFFIRIS AG Parkinson's candidate PD01A has begun.PD01A targets alpha-synuclein and induces antibodies to neutralize its toxic impact potentially modifying the diseases course. This is a "First-in-man""First-in kind"trial that will enroll 32 patients to be the pioneers of this immunotherapy of Parkinson's disease.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment